赛妥珠单抗聚乙二醇化产物 - 用于难治性葡萄膜炎的肿瘤坏死因子抑制剂。
Certolizumab pegol - Tumor necrosis factor inhibitor for refractory uveitis.
作者信息
Sharon Yael, Chu David S
机构信息
Metropolitan Eye Research and Surgery Institute, Palisades Park, NJ, USA.
Institute of Ophthalmology and Visual Science, New Jersey Medical School, Rutgers University, Newark, NJ, USA.
出版信息
Am J Ophthalmol Case Rep. 2020 Feb 27;18:100633. doi: 10.1016/j.ajoc.2020.100633. eCollection 2020 Jun.
PURPOSE
The purpose of our study is to report our experience with the use of certolizumab pegol in patients with refractory non-infectious uveitis.
OBSERVATIONS
We present a case series of three patients with non-infectious uveitis, treated with twice-monthly subcutaneous certolizumab pegol. All of our patients had different types of uveitis and different underlying etiologies. All of our patients had previously failed various immunomodulatory therapies and/or were intolerant to at least one tumor necrosis factor (TNF) inhibitor agent. Following initiation of therapy with certolizumab pegol, all three patients showed significant clinical improvement of their ocular inflammation. No adverse events from treatment with certolizumab pegol were observed.
CONCLUSIONS AND IMPORTANCE AND IMPORTANCE
We observed positive outcomes using the TNF inhibitor certolizumab pegol for the treatment of patients with refractory, non-infectious uveitis, in whom therapy with other TNF inhibitors was inadequate or in which there were tolerance issues. Patients who have failed other TNF inhibitors may benefit from treatment with certolizumab pegol.
目的
我们研究的目的是报告我们在难治性非感染性葡萄膜炎患者中使用聚乙二醇化赛妥珠单抗的经验。
观察结果
我们呈现了一个由三名非感染性葡萄膜炎患者组成的病例系列，他们接受了每月两次的皮下注射聚乙二醇化赛妥珠单抗治疗。我们所有的患者患有不同类型的葡萄膜炎且病因各异。我们所有的患者此前各种免疫调节疗法均告失败和/或对至少一种肿瘤坏死因子（TNF）抑制剂不耐受。在用聚乙二醇化赛妥珠单抗开始治疗后，所有三名患者眼部炎症均有显著临床改善。未观察到聚乙二醇化赛妥珠单抗治疗的不良事件。
结论及意义
我们观察到使用TNF抑制剂聚乙二醇化赛妥珠单抗治疗难治性非感染性葡萄膜炎患者取得了积极结果，这些患者使用其他TNF抑制剂治疗效果不佳或存在耐受性问题。其他TNF抑制剂治疗失败的患者可能从聚乙二醇化赛妥珠单抗治疗中获益。
Zotero 插件